Pyridopyrroloquinoxaline

A substituted pyridopyrroloquinoxaline, or more specifically a substituted octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, also known as a substituted heterocycle fused γ-carboline, is a further-cyclized and substituted tetracyclic derivative of the tricyclic alkaloid γ-carboline as well as an analogue of the atypical antipsychotic lumateperone. They can additionally be thought of as analogues of cyclized tryptamines like the β-carbolines or harmala alkaloids such as harmaline, but are not technically tryptamines themselves.

Pyridopyrroloquinoxalines are notable for their varying interactions with the serotonin 5-HT2A receptor as well as with other monoamine receptors. Lumateperone and deulumateperone are serotonin 5-HT2A receptor antagonists with antipsychotic properties, IHCH-7113 is a putatively psychedelic serotonin 5-HT2A receptor full agonist with a robust head-twitch response in rodents, and IHCH-7086, IHCH-7079, and ITI-1549 are putatively non-hallucinogenic β-arrestin-biased serotonin 5-HT2A receptor partial agonists with psychoplastogenic and/or antidepressant-like effects in preclinical studies. The broad receptor interactions of some of these compounds have been studied.

Pyridopyrroloquinoxalines with serotonin 5-HT2A receptor agonistic activity such as IHCH-7113 and IHCH-7086 were first described in the scientific literature by Dongmei Cao and colleagues by 2022. As of 2025, ITI-1549 is under development by Intra-Cellular Therapies for the treatment of mood and other psychiatric disorders.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.